Last reviewed · How we verify
Atorvastatin, high vs low dose
Atorvastatin, marketed by Hippocration General Hospital, is a well-established drug in the lipid-lowering market with a key composition patent expiring in 2028. The drug's primary strength lies in its robust clinical profile and widespread use, positioning it as a leading therapy in its class. The primary risk to Atorvastatin's market position is the impending patent expiry, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Atorvastatin, high vs low dose |
|---|---|
| Also known as | Atorvastatin high vs low dose in ischemic heart disease |
| Sponsor | Hippocration General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pleiotropic Effects of Atorvastatin in High Cardiovascular Risk Patients (PHASE4)
- Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atorvastatin, high vs low dose CI brief — competitive landscape report
- Atorvastatin, high vs low dose updates RSS · CI watch RSS
- Hippocration General Hospital portfolio CI